| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $60.23 | $60.23 (0%) | 🛒 Add to cart |
| 2 | $50.19 | $120.46 $100.38 (17%) | 🛒 Add to cart |
| 3 | $43.50 | $180.69 $130.50 (28%) | 🛒 Add to cart |
| 4 | $42.66 | $240.92 $170.65 (29%) | 🛒 Add to cart |
| 5 | $40.15 | $301.14 $200.76 (33%) | 🛒 Add to cart |
| 6 | $38.48 | $361.37 $230.88 (36%) | 🛒 Add to cart |
| 7 | $37.28 | $421.60 $260.99 (38%) | 🛒 Add to cart |
| 8 | $36.39 | $481.83 $291.11 (40%) | 🛒 Add to cart |
| 9 | $34.58 | $542.06 $311.18 (43%) | 🛒 Add to cart |
| 10 | $33.13
Best per bottle | $602.29 $331.26 (45%) | 🛒 Add to cart |
Synonyms | |||
More info:
bimat
Bimat represents one of those rare clinical tools that actually delivers on its theoretical promise - a sustained-release bimatoprost ocular implant for glaucoma management that’s fundamentally changing how we approach intraocular pressure control. When I first encountered the prototype seven years ago during a research symposium, I’ll admit I was skeptical. We’d seen so many “revolutionary” delivery systems fail in translation from lab to clinic. ## 1. Introduction: What is Bimat?
careprost
Careprost represents one of those interesting cases where an existing medication found an entirely new therapeutic application through careful clinical observation. Originally developed as a prostaglandin analog for glaucoma management, its remarkable side effect of enhancing eyelash growth created an entirely new category in cosmetic dermatology. The active component, bimatoprost, works through prostaglandin receptor-mediated pathways that extend far beyond intraocular pressure reduction. I remember when we first started noticing the eyelash changes in our glaucoma patients back in 2008.
lumigan
Bimatoprost ophthalmic solution 0.03% - that’s what we’re really talking about when we discuss Lumigan. It arrived in our practice back in 2001, and I remember the initial skepticism among our ophthalmology group. We’d been through the prostaglandin analog revolution with latanoprost, but this new compound promised something different in the glaucoma arsenal. The first thing that struck me was the unusual mechanism - a synthetic prostamide that doesn’t quite fit the classic prostaglandin pathway yet produces remarkable IOP reduction.
xalatan
Latanoprost ophthalmic solution, marketed under the brand name Xalatan among others, represents a cornerstone in the pharmacological management of open-angle glaucoma and ocular hypertension. It’s a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure (IOP), which is the primary modifiable risk factor for glaucomatous optic nerve damage and visual field loss. Since its introduction, it has fundamentally changed the treatment paradigm, often serving as a first-line agent due to its efficacy, once-daily dosing, and generally favorable systemic side effect profile.
abana
Product Description Abana represents one of those formulations that initially puzzled me when I first encountered it in practice - a comprehensive herbal supplement with roots in Ayurvedic medicine, primarily indicated for cardiovascular support. What struck me during my early years at the Cleveland Clinic was how this multi-herb preparation kept appearing in patients’ medication lists, particularly among those with familial hyperlipidemia patterns. The formulation contains a sophisticated blend of Terminalia arjuna, Inula racemosa, Commiphora mukul, and several other botanicals that work synergistically - something we rarely see in single-component pharmaceuticals.
abhigra
Product Description: Abhigra represents a novel class of medical-grade nutraceutical devices that combines standardized botanical extracts with a patented sublingual delivery system. Unlike conventional supplements, its mechanism relies on transmucosal absorption bypassing first-pass metabolism, which we’ve observed yields significantly faster onset of action—particularly valuable for acute inflammatory episodes. The development team spent three years battling stability issues with the nanoemulsion matrix before discovering that alternating temperature cycles during production actually enhanced bioactive preservation, contrary to our initial assumptions.
abilify
Aripiprazole, marketed under the brand name Abilify, represents a significant advancement in psychopharmacology as a second-generation antipsychotic medication. Unlike first-generation antipsychotics that primarily function as dopamine D2 receptor antagonists, aripiprazole exhibits a unique mechanism as a partial dopamine agonist. This pharmacological profile allows it to stabilize dopamine activity rather than simply blocking it, creating what many clinicians describe as a “dopamine stabilizer” effect. The medication has received FDA approval for multiple psychiatric conditions including schizophrenia, bipolar disorder, major depressive disorder (as adjunct treatment), Tourette’s disorder, and irritability associated with autistic disorder.
Acamprol: Targeted Neurological Support for Hyperexcitability Disorders - Evidence-Based Review
In my early neurology practice, we kept hitting walls with certain patients—the ones with persistent neurological irritability where standard GABAergics either failed or caused unacceptable sedation. That’s when our hospital’s pharmacology team first showed me the molecular structure of what would become Acamprol. It wasn’t another benzodiazepine analog or some exotic plant extract, but a synthetic compound mimicking taurine’s neuromodulatory properties. We initially called it “Calcium Acetylhomotaurinate” until the brand name stuck.
Accufine: Advanced Continuous Glucose Monitoring for Diabetes Management - Evidence-Based Review
Product Description: Accufine represents a significant advancement in non-invasive glucose monitoring technology. It’s a continuous glucose monitoring (CGM) system that uses micro-needle sensor technology combined with advanced algorithms to provide real-time interstitial fluid glucose readings without the traditional fingerstick calibration. The device consists of a discreet wearable sensor that transmits data to both a dedicated reader and compatible smartphone applications, allowing for comprehensive glucose trend analysis and predictive alerts. I remember when we first started developing this technology back in 2018 - our team was divided between pursuing traditional electrochemical sensing versus this novel optical approach.